

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
11 March 2004 (11.03.2004)

PCT

(10) International Publication Number
WO 2004/019960 A2

(51) International Patent Classification⁷: **A61K 35/00**

MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number:
PCT/IN2003/000289

(22) International Filing Date: 27 August 2003 (27.08.2003)

(25) Filing Language: English

(26) Publication Language: English

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(30) Priority Data:
779/MUM/2002 28 August 2002 (28.08.2002) IN

Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i)) for all designations
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- of inventorship (Rule 4.17(iv)) for US only

(71) Applicant (*for all designated States except US*): LUPIN LTD. [IN/IN]; 159, CST Road, Kalina, Santacruz (E), 400 098 Mumbai (IN).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): ARORA, Sudershan, Kunar [US/IN]; Lupin Ltd. (Research Park), 46A/47A, Nande Village, Taluka Mulshi, 411 042 Pune (IN). SRIVASTAVA, Vandita [IN/IN]; Lupin Ltd. (Research Park), 46A/47A, Nande Village, Taluka Mulshi, 411 042 Pune (IN). ADDEPALLI, Veeranjanyulu [IN/IN]; Lupin Ltd. (Research Park), 46A/47A, Nande Village, Taluka Mulshi, 411 042 Pune (IN). NATESAN, Sridhar [IN/IN]; Lupin Ltd. (Research Park), 46A/47A, Nande Village, Taluka Mulshi, 411 042 Pune (IN). GOEL, Rajan [IN/IN]; Lupin Ltd. (Research Park), 46A/47A, Nande Village, Taluka Mulshi, 411 042 Pune (IN).

(74) Agents: MAJUMDAR, S. et al.; S. MAJUMDAR & CO., 5, Harish Mukherjee Road, 700 025 Kolkata (IN).

Published:

- without international search report and to be republished upon receipt of that report

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) **Title:** HERBAL EXTRACT COMPRISING A MIXTURE OF SAPONINS OBTAINED FROM SAPINDUS TRIFOLIATUS FOR ANTICONVULSANT ACTIVITY

(57) **Abstract:** A pharmaceutical composition comprising a herbal extract, comprising a mixture of saponins prepared from the pericarp of *Sapindus trifoliatus*, with binding affinities for the receptor sites viz. GABA-A agonist site, Glutamate-AMPA site, Glutamate-Kainate site, Glutamate-NMDA agonistic site, Glutamate-NMDA glycine (strychnine insensitive) site and Sodium channel (site 2). having major mediatory role in anticonvulsant activity. A process for preparation of the herbal extract; isolation of six pure compounds from the mixture of saponins in the aqueous extract; and a pharmaceutical composition comprising the said extract in combination with pharmaceutically acceptable additives. A method of prophylactic treatment of migraine through anticonvulsant activity of the composition by its administration through intranasal route.

WO 2004/019960 A2